$PVSP (“Pervasip” or the “Company”), a developer

New Post Public Reply Private Reply Replies (0) Message Board
budfoxfun
148
$PVSP (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its 3rd Quarter ended August 31, 2022.

“Q3 2022 shows material signs of improvement over Q2 2022 reflecting our ongoing operational focus. As stated before, we continue to pursue our strategic goals even during these difficult market conditions as evidenced by our recent agreements on terms for the acquisition of the Emerald City Cultivation and Dabco brands. Our operational and financial focus on rationalizing our business, shedding underperforming assets, and increasing production yields by our independent cultivators continues to proceed and have allowed us to continue with additional market share capture. Investing in Cannabis is not for the faint of heart and we believe we are building a solid foundation for years to come which takes time, patience, and relentless focus on fundamentals. In an industry that does not have access to traditional financing, our options are limited and expensive,” said German Burtscher, Pervasip’s CEO. “We slowed the rollout of our new concentrate brands which we licensed for Q3 deployment and instead focused on an outright acquisition as the opportunity became available. That resulted in not meeting the forecasted revenue from the new product lineup for Q3. We are also pursuing a conservative approach to working within the complicated tax environment our industry is confronted with. Ongoing work in support of the audit process and a recent court ruling that impacts the cannabis industry caused us to change our estimates for tax liability dating back to prior periods 2017 – 2020, which we booked in Q3.”

The Company continues to focus on moving available bulk inventory into higher margin brands with a focus on margin capture and is seeing promising early results.

Third Quarter 2022 Financial Results

Q3 2022 versus Q2 2022

Q3 2022 operating results improved over Q2 2022, tracking with ongoing efforts to shift bulk sales to higher margin brands combined with relative COGs reductions, even when adjusted for inventory.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arclin's Bold Bet: Expanding Nomex Capacity in Spain

Updated Category News Views 5

Arclin's Strategic Move for Nomex® Expansion Looks like Arclin’s not messing around. They're throwing some serious cash down in Asturias, Spain, to ramp up production of Nomex®—a material hotter than a blacktop in July with demand surging across aerospace, electric vehicles, and defense sectors. "When we bought the Nomex® business, we committed to investing in its...

Continue Reading
Unicycive Faces Stock Plunge and Legal Woes After FDA Setback

Updated Category News Views 5

Unicycive's Rough Ride: Not Just a Bump Picture this: Your stock takes a nosedive over 39% in a day, just after a critical drug application gets slammed by the FDA—for the second time. That’s the story with Unicycive Therapeutics, Inc., ticker NASDAQ: UNC, a company that's been handing out one nail-biting moment after another to its investors. It's not just a minor...

Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

Updated Category News Views 0

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Continue Reading
Side Bolsters Art Division with Roboto Acquisition

Updated Category News Views 7

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

Continue Reading
S&T Bancorp Hits Record Highs in Q3 2026

Updated Category News Views 3

Surpassing Expectations with Record Metrics Well, if it isn’t another stellar quarter for S&T Bancorp (NASDAQ:STBA). The folks over in Indiana, PA, just threw down some serious numbers. The third quarter of 2026 saw net income climbing to $38.6 million, up from $36.6 million last quarter. That's a decent hike if you ask me. But what really stole the spotlight here was...

Continue Reading
Savarese Joins RID to Drive Diagnostic Innovation

Updated Category News Views 5

A Seasoned Leader Bolsters RID's Ambitions Mario Savarese has joined Rapid Infection Diagnostics Inc.'s Strategic Advisory Board, and let me tell ya, this move's got potential. Appointing a heavyweight like Savarese as an advisor isn’t just a nod to his hefty resume. It’s about vaulting a burgeoning company into the big leagues. He's got over 20 years steering a ship...

Continue Reading
Tairex's AI System Targets Global Healthcare Gaps

Updated Category News Views 6

AI Meets Human Expertise in Clinical Decision-Making Look, in the labyrinth of healthcare, we’re seeing a revolution with AI stepping in—not to replace the doctor, but to stand alongside them like a trusty assistant. Tairex, from the halls of Tsinghua University's Institute for AI Industry Research (AIR), has thrown its hat into this ring by unveiling their...

Continue Reading
Montega Kicks Off Agilyx Sponsored Equity Research

Updated Category News Views 1

A Fresh Take on Agilyx's Market Standing Alright, folks. Agilyx ASA just got a new ticket for the analytical rodeo as Montega AG dives into sponsored equity research on the company. For those who aren't fluent in the arcane dialect of stock enthusiasts like yours truly, this means Agilyx now has another sharp set of eyes evaluating their every move, and let me tell you,...

Continue Reading
Nel ASA Welcomes Morten Holum as New CEO by 2027

Updated Category News Views 7

Nel ASA's New Leader Announced In the latest shake-up at Nel ASA (OSE: NEL), Morten Holum is getting ready to take the reins as CEO. By May 1, 2027, Holum will step into the shoes left by Håkon Volldal. And folks, this isn't your average leadership swap. Holum brings a hefty toolkit to this hydrogen powerhouse, having been part of the action across the hydrogen value...

Continue Reading
Amcor's Q3 2026 Results Loom: What's at Stake?

Updated Category News Views 3

Anticipation Builds for Amcor's Q3 2026 Financials Well, here we are again, staring down the barrel of another quarterly earnings report from Amcor plc (NYSE: AMCR). They've circled November 4th, 2026, in red on their calendars to dish out the numbers after the U.S. market's last bell rings. Investors, analysts, and the peanut gallery will be tuning in, and why not? At a...

Continue Reading

Top 5 Most Recently Viewed Articles

Ontex Group to Announce Shareholding Details Soon

Updated Category News Views 51

Significant Shareholding Notification by Ontex Group NV Ontex Group NV is committed to transparency and compliance with regulatory requirements. Recently, the company disclosed a significant shareholding notification that it received regarding Black Creek Investment Management Inc. This notification aligns with the Belgian Law concerning significant shareholdings in...

Continue Reading
TriNet Set to Announce First Quarter Results Soon

Updated Category News Views 154

TriNet's Upcoming Financial Report Announcement TriNet (NYSE: TNET), a prominent provider of human resources solutions tailored for small and medium-sized businesses (SMBs), is gearing up to reveal its financial results for the first quarter previously ended on March 31. The announcement is set to take place before the U.S. market opens on April 25. Details of the...

Continue Reading
PTC Therapeutics: Upcoming Q3 2025 Financial Results Call

Updated Category News Views 166

PTC Therapeutics Plans Third Quarter 2025 Financial Call PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that it will host a conference call to discuss its financial results for the third quarter of 2025. This upcoming event is set to take place on November 4 at 4:30 p.m. ET. It promises to provide valuable insights into the company's performance and strategic...

Continue Reading
Enhancing Maritime Safety with PntGuard™ Against Spoofing Threats

Updated Category News Views 201

Introducing PntGuard™ for Enhanced Maritime Security PntGuard™ is a revolutionary maritime-security solution designed to protect vessels from the dangers of GNSS spoofing and jamming. As the maritime sector faces growing threats from malicious disruptions of GNSS signals, PntGuard™ stands as a beacon of reliability, ensuring crews can navigate with confidence. This...

Continue Reading
Scienture Holdings Expands Market Reach with Arbli™ Agreements

Updated Category News Views 162

Scienture Holdings Enhances Healthcare Access with New Agreements Signifying a potential reach into about 20% of the U.S. institutional market, Scienture Holdings, Inc. (NASDAQ: SCNX) is paving the way for Arbli™ (losartan potassium) across a range of healthcare facilities. The U.S. losartan market, valued at $256 million annually, witnesses around 71 million...

Continue Reading